Business Wire

MA-ELECTRA-VEHICLES

Share
Electra Vehicles, Inc. Welcomes Electric Vehicle Industry Expert Alexander Hitzinger to Board of Directors

On April 5, 2022, automotive industry leader Alexander (Alex) Hitzinger was appointed to the Board of Directors at Electra Vehicles, Inc. as an Independent Board Member. The appointment marks another critical milestone for the growing AI battery software startup as the company expands its expert roster of electric vehicle leaders from the transportation industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220410005015/en/

Hitzinger boasts an extensive engineering and leadership career where he led key autonomous and electric vehicle projects. His career began at Toyota as a development engineer before working in the Formula 1 world as Head of Formula 1 Development at Cosworth and Head of Advanced Technologies at Red Bull’s Formula 1 Team. His penchant for leading cutting edge automotive technology projects led him to serve as Technical Director for the three times victorious Porsche 919 at the 24 Hours of Le Mans and Head of Product Design at Apple for Project Titan before co-founding and serving as CEO at ARTEMIS, where he lead the creation of a visionary autonomous vehicle concept. Most recently, Hitzinger served as Senior Vice President of Autonomous Driving at VW Group and Member of the Executive Board VWN, where he was involved in the development of the ID Buzz. With more than 20 years of experience in the automotive and electric vehicle industries, Hitzinger begins a new phase of his career with the aim of supporting promising young companies with disruptive technologies as they enter the automotive and electric vehicle world stage.

“I am looking for outstanding companies, with industry leading technologies, where I can help the management in deriving a successful strategy for scaling the company and the technology. Electra Vehicles, Inc. is exactly this type of company,” says Hitzinger. “The electrification of transportation is in full swing, but in many areas of the technology stack, there are still outdated technologies deployed. Electra is closing one of these gaps with its sophisticated battery performance management, and therefore I couldn’t be happier about joining Electra’s Board of Directors.”

CEO and Co-founder of Electra Vehicles, Fabrizio Martini, expresses his delight at welcoming Hitzinger to the Board: “The Electra team is honored, proud, and glad to welcome on its Board of Directors an extraordinary visionary like Alex Hitzinger. Alex is a world-renowned expert and award-winning talent in the Mobility sector. His experience, knowledge, and vision will guide Electra Vehicles, Inc. to make a significant global impact. I am genuinely excited to start partnering with Alex to bring the most advanced ML/AI-based technology worldwide for battery management solutions in the marketplace to enhance today’s transition to electric transportation.”

About Electra Vehicles, Inc.

Electra Vehicles is a leading B2B AI software company headquartered in Boston, MA, USA with a presence in Italy that produces embedded and Cloud-connected software to optimize the performance of electric vehicle battery systems for range, lifetime, charging, and safety benefits. Electra’s onboard EVE-Ai™ 360 Adaptive Controls and Cloud-based EVE-Ai™ Fleet Analytics are software that provide battery system performance insights, battery-conscious driver recommendations, and intelligent charging control strategies based on a continuously updating Adaptive Cell Model, making Electra’s EVE-Ai™ a necessity for electrified applications worldwide. In 2021, Electra Vehicles, Inc. became a BlackBerry IVY Fund investee and is a proud member of the BlackBerry IVY ecosystem.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye